“We are pleased that we were able to reach a compromise on the bill and commend the tireless advocacy of all stakeholders who were involved, especially the legislators for their thoughtful consideration,” Curaleaf Maryland President Justin Somers said in an email. “As a result of the legislation, Curaleaf and other operators will now be able to invest in state-of-the-art testing, partner with top universities on critical research, offer a greater array of products and most importantly lower prices for patients.”